Career history of Anthony E. Bolton
Former positions of Anthony E. Bolton
| Companies | Position | Start | End |
|---|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Tech/Sci/R&D Officer | 01/01/1992 | 01/01/2008 |
| Founder | 01/01/1992 | 01/01/2008 | |
| Sheffield Hallam University | Corporate Officer/Principal | 01/01/1985 | 01/01/1995 |
| InterMune Life Sciences, Inc. | Chief Tech/Sci/R&D Officer | 01/01/1992 | 01/01/1995 |
| Founder | 01/01/1992 | 01/01/1995 | |
| Jessop Hospital For Women | Corporate Officer/Principal | 01/01/1992 | 01/01/1995 |
| St. Bartholomew's Hospital | Corporate Officer/Principal | 01/01/1976 | 01/01/1979 |
| CARDIOL THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 19/01/2017 | - |
| Founder | 19/01/2017 | - |
Training of Anthony E. Bolton
| University of London | Undergraduate Degree |
| The University of Reading | Doctorate Degree |
Statistics
International
| United Kingdom | 6 |
| Canada | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Corporate Officer/Principal | 3 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private companies | 4 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
| St. Bartholomew's Hospital | |
| InterMune Life Sciences, Inc. | |
| Jessop Hospital For Women |
- Stock Market
- Insiders
- Anthony E. Bolton
- Experience
